GSK, Nuvalent
Digest more
The acquisition is set to give GSK ownership of three drug candidates for lung cancer, two of which are under FDA review for approval this year.
The FTSE 100 index dropped by 0.3% on Tuesday, primarily influenced by GSK's decision to acquire U.S.-based drug developer Nuvalent for $10.6 billion. The acquisition is part of GSK's strategy to enhance its lung cancer treatment portfolio.